Abstract
Undifferentiated pleomorphic sarcoma (UPS) is one of the common subtypes of soft tissue sarcoma (STS). Alternative therapy is needed for patients who are not suitable for chemotherapy. Antiangiogenic agents are approved for the treatment of advanced STS. In the SARC028 study, PD-1 inhibitor showed initial efficacy on UPS. The combination of antiangiogenic agent and PD-1 inhibitor may have synergistic effects. This single-arm phase II study aims to evaluate the efficacy and safety of anlotinib combined with toripalimab in the first-line treatment of patients with unresectable or metastatic UPS.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
